LabCorp and Ciox Health, a health information management company, announced an agreement to build a U.S.-based COVID-19 patient data registry, according to a news release.
The registry will be made up of HIPAA-compliant de-identified data sets, allowing for clinical research and analyses related to COVID-19.
The registry will include de-identified data sets from the 500,000 tests that LabCorp has performed since first making its COVID-19 test available March 5. The data sets also will include additional longitudinal medical record data from Ciox Health’s Data Fit platform.
Over time, the two companies may expand the data sets to include information from healthcare providers or state and federal public health organizations.
LabCorp and Ciox Health expect the data sets to yield insights into possible host and environmental factors that drive susceptibility to, or protection from, the SARS-CoV-2 viral infection, along with risk factors associated with the severity of disease at presentation and associated outcomes based on interventions.
